Biocryst Pharmaceuticals Inc
BCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882796
No open-market purchases or sales by Biocryst Pharmaceuticals Inc insiders were filed in the last 90 days; 320 institutions reported holding it in 13F filings for Q2 2026, worth $2.61B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:08 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 10, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $874.8M | $450.7M | $331.4M | $270.8M | $157.2M |
| Cost of revenue | $19.1M | $12.3M | $4.48M | $6.41M | $7.23M |
| Research and development | $166.1M | $174.6M | $216.6M | $253.3M | $208.8M |
| Selling, general and administrative | $348.6M | $266.1M | $213.9M | $159.4M | $118.8M |
| Operating income | $341.0M | -$2.54M | -$103.7M | -$148.4M | -$177.7M |
| Interest expense | – | – | $108.2M | $99.1M | $59.3M |
| Income tax | $3.53M | $1.93M | $310.0K | $2.73M | $2.25M |
| Net income | $263.9M | -$88.9M | -$226.5M | -$247.1M | -$184.1M |
| EPS, basic | $1.26 | $-0.43 | $-1.18 | $-1.33 | – |
| EPS, diluted | $1.21 | $-0.43 | $-1.18 | $-1.33 | – |
| Weighted shares, basic | 209.9M | 206.7M | 192.2M | 185.9M | – |
| Weighted shares, diluted | 218.6M | 206.7M | 192.2M | 185.9M | 179.1M |
| Margins and growth | |||||
| Operating margin | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% |
| Net margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% |
| Revenue growth, year over year | +94.1% | +36.0% | +22.4% | +72.3% | +782.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 10, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $89.7M | $104.7M | $110.6M | $304.8M | $504.4M |
| Short-term investments | $185.0M | – | – | – | – |
| Accounts receivable | $106.8M | $79.1M | $57.0M | $50.6M | $29.4M |
| Inventory | $5.40M | $31.3M | $28.7M | $27.5M | $15.8M |
| Total current assets | $404.3M | $422.0M | $496.0M | $516.5M | $566.1M |
| Property, plant and equipment | $8.78M | $7.78M | $7.91M | $8.62M | $8.71M |
| Total assets | $514.2M | $490.4M | $517.0M | $550.0M | $588.2M |
| Accounts payable | $15.8M | $11.6M | $20.9M | $14.4M | $27.8M |
| Total current liabilities | $196.1M | $160.4M | $150.0M | $105.5M | $103.7M |
| Long-term debt | $0 | $314.9M | $303.2M | $231.6M | $136.1M |
| Total liabilities | $633.3M | $966.4M | – | – | – |
| Shareholders' equity | -$119.2M | -$475.9M | -$455.5M | -$294.6M | -$107.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 10, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | $347.4M | -$52.0M | -$95.1M | -$161.8M | -$142.2M |
| Capital expenditures | $2.47M | $1.12M | $2.17M | $1.35M | $2.38M |
| Free cash flow | $344.9M | -$53.1M | -$97.3M | -$163.2M | -$144.5M |
| Depreciation and amortization | $1.39M | $1.25M | $1.66M | $1.44M | $777.0K |
| Stock-based compensation | $85.1M | $65.4M | $55.6M | $44.7M | $34.6M |
| Investing cash flow | -$13.7M | $52.6M | -$131.5M | -$128.2M | $15.8M |
| Financing cash flow | -$349.9M | -$5.76M | $32.5M | $88.0M | $359.7M |
| Net change in cash | -$15.0M | -$6.12M | -$193.8M | -$201.5M | $233.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 9.7% | 14.5% | 16.8% | 16.5% | 22.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 257.3M | +22.2% | SEC |
| Jul 31, 2026 | 255.5M | +21.7% | SEC |
| Apr 30, 2026 | 254.2M | +21.5% | SEC |
| Feb 20, 2026 | 250.8M | +20.0% | SEC |
| Oct 31, 2025 | 210.5M | +1.6% | SEC |
| Jul 31, 2025 | 209.9M | +1.5% | SEC |
| Apr 30, 2025 | 209.3M | +1.4% | SEC |
| Feb 20, 2025 | 209.0M | +1.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.